KineMed Inc.
Brief Description
KineMed is a field-leading US biotech company that works with major pharmaceutical and biotechnology companies to produce data on target engagement, toxicity and disease progression to accelerate drug development and reduce the overall costs and risks.
Inventor
Tech Category
- Medical Diagnostics
In the News
- KineMed Enters Into Strategic Proteomic Biomarker Discovery Collaboration with Pfizer Inc. 1/4/16
- KineMed Announces License Agreement to Develop Late-Stage Synthetic Ghrelin 9/24/15
- KineMed and Camino Partnership Announce Collaboration to Create Portfolio of Clinical Drug Candidates 4/23/15
- KineMed to Present “Capturing Value by De-risking and Advancing Therapeutics” at the 17th Annual BIO CEO & Investor Conference 2/9/15
- KineMed Receives U.S. Patent Allowance for Noscapine to Treat ALS, Parkinson's Disease and Diabetic Neuropathy 9/4/14
- KineMed prepares for $51 million IPO 1/8/14
- KineMed Announces Agreement with Amgen to Develop Kinetic Biomarkers of Brain Proteinopathies 10/15/13
- Novel Atherosclerosis-Reversing, Heart Disease Therapy Wins NIH Clinical Development Grant 4/10/12
- KineMed Inks Deal with Pfizer to Use Dynamic Proteomics Platform in Diabetes Drug Development 2/3/12
- David Fineman 6/12/05
© 2022 Regents of the University of California. All Rights Reserved.